Obsessive-compulsive symptoms in patient with schizophrenia: The influence of disorganized symptoms, duration of schizophrenia, and drug resistance.
consensus
dimensional obsessive-compulsive symptoms scale
disorganized symptoms
duration
obsessive–compulsive symptoms
positive and negative syndrome scale
resistant schizophrenia
schizophrenia
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
12
2022
accepted:
08
02
2023
entrez:
16
3
2023
pubmed:
17
3
2023
medline:
17
3
2023
Statut:
epublish
Résumé
Schizophrenia is a chronic mental disorder with a many-faced clinical presentation. Obsessive-compulsive symptoms are often part of it. The characteristics of the clinical picture and the course of schizophrenia are factors related to both the resistance and the manifestation of obsessive-compulsive symptoms. Our study aims to establish the relationship between the peculiarities of the schizophrenia process and the influence of resistance on the expression of obsessive-compulsive symptoms. A study was conducted on 105 patients with schizophrenia. Of them, 39 are men and 66 are women. The evaluation of the effectiveness of the treatment showed that 45 were resistant to the applied therapy, while the remaining 60 responded. Clinical assessment of patients was performed using the Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS). Assessment of obsessive-compulsive symptoms (OCS) was conducted with the Dimensional obsessive-compulsive symptoms scale (DOCS). In 34% of all patients, we found clinically expressed obsessive-compulsive symptoms. In 40% of the patients with resistance, we found clinically expressed obsessive-compulsive symptoms, which are within the range of moderately expressed. In 30% of the patients in clinical remission, we found obsessive-compulsive symptoms, but mildly expressed. We found a statistically significant relationship between the severity of OCS and the disorganized symptoms and the duration of the schizophrenia process. No differences were found in the expression of OCS in patients of both sexes. We registered both an increased frequency and an increased expression of obsessive-compulsive symptoms in patients with resistant schizophrenia. These symptoms were positively associated with disorganized symptoms and duration of schizophrenia. No relationship was established with the positive, negative symptoms, as well as with the gender distribution.
Sections du résumé
Background
UNASSIGNED
Schizophrenia is a chronic mental disorder with a many-faced clinical presentation. Obsessive-compulsive symptoms are often part of it. The characteristics of the clinical picture and the course of schizophrenia are factors related to both the resistance and the manifestation of obsessive-compulsive symptoms. Our study aims to establish the relationship between the peculiarities of the schizophrenia process and the influence of resistance on the expression of obsessive-compulsive symptoms.
Methods
UNASSIGNED
A study was conducted on 105 patients with schizophrenia. Of them, 39 are men and 66 are women. The evaluation of the effectiveness of the treatment showed that 45 were resistant to the applied therapy, while the remaining 60 responded. Clinical assessment of patients was performed using the Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS). Assessment of obsessive-compulsive symptoms (OCS) was conducted with the Dimensional obsessive-compulsive symptoms scale (DOCS).
Results
UNASSIGNED
In 34% of all patients, we found clinically expressed obsessive-compulsive symptoms. In 40% of the patients with resistance, we found clinically expressed obsessive-compulsive symptoms, which are within the range of moderately expressed. In 30% of the patients in clinical remission, we found obsessive-compulsive symptoms, but mildly expressed. We found a statistically significant relationship between the severity of OCS and the disorganized symptoms and the duration of the schizophrenia process. No differences were found in the expression of OCS in patients of both sexes.
Conclusion
UNASSIGNED
We registered both an increased frequency and an increased expression of obsessive-compulsive symptoms in patients with resistant schizophrenia. These symptoms were positively associated with disorganized symptoms and duration of schizophrenia. No relationship was established with the positive, negative symptoms, as well as with the gender distribution.
Identifiants
pubmed: 36923524
doi: 10.3389/fpsyt.2023.1120974
pmc: PMC10008879
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1120974Informations de copyright
Copyright © 2023 Panov and Panova.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Harv Rev Psychiatry. 2015 Jan-Feb;23(1):19-27
pubmed: 25563566
Diagnostics (Basel). 2021 Jan 08;11(1):
pubmed: 33435624
Behav Neurol. 1998;11(4):197-204
pubmed: 11568420
Psychophysiology. 2022 Dec;59(12):e14122
pubmed: 35671393
J Psychopharmacol. 2014 Jun;28(6):596-602
pubmed: 24429223
Acta Psychiatr Scand. 2011 Feb;123(2):136-46
pubmed: 20880068
Front Hum Neurosci. 2009 Oct 26;3:36
pubmed: 19893755
Am J Psychiatry. 1997 Apr;154(4):475-82
pubmed: 9090333
Front Pharmacol. 2013 Aug 09;4:99
pubmed: 23950745
Cells. 2022 Aug 21;11(16):
pubmed: 36010683
Biomedicines. 2021 May 06;9(5):
pubmed: 34066395
Front Psychiatry. 2022 Aug 10;13:995455
pubmed: 36032251
Innov Clin Neurosci. 2015 Jul-Aug;12(7-8):12-9
pubmed: 26351619
Clin Neurosci. 1995;3(2):89-97
pubmed: 7583624
Prog Neuropsychopharmacol Biol Psychiatry. 2003 May;27(3):333-46
pubmed: 12691768
Prog Neuropsychopharmacol Biol Psychiatry. 2006 May;30(3):327-37
pubmed: 16412548
Eur Psychiatry. 2011 Jan;26(1):45-56
pubmed: 20980130
Am J Psychiatry. 1999 Dec;156(12):1998-2000
pubmed: 10588421
Indian J Psychiatry. 2019 Jan;61(Suppl 1):S51-S57
pubmed: 30745677
J Nerv Ment Dis. 2002 Nov;190(11):725-32
pubmed: 12436011
J Psychiatr Res. 2021 Sep;141:293-300
pubmed: 34274840
Arch Gen Psychiatry. 1998 Feb;55(2):145-52
pubmed: 9477928
Diagnostics (Basel). 2022 Mar 25;12(4):
pubmed: 35453850
Biol Psychiatry. 2003 Aug 15;54(4):437-43
pubmed: 12915288
Compr Psychiatry. 1995 Jul-Aug;36(4):267-70
pubmed: 7554870
Int Clin Psychopharmacol. 2023 Mar 1;38(2):102-109
pubmed: 36719338
Front Psychiatry. 2022 Apr 05;13:868285
pubmed: 35479496
Clin EEG Neurosci. 2019 Mar;50(2):88-99
pubmed: 30280595
Int Clin Psychopharmacol. 2000 Sep;15(5):297-301
pubmed: 10993132
Br J Psychiatry. 1986 Nov;149:661-2
pubmed: 3545358
Trends Neurosci. 2022 Jul;45(7):504-506
pubmed: 35577621
BMC Psychiatry. 2013 May 30;13:156
pubmed: 23721089
Neuropsychopharmacology. 2016 Sep;41(10):2587-95
pubmed: 27143602
J Affect Disord. 2021 May 1;286:78-79
pubmed: 33714173
Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Nov;2(8):655-663
pubmed: 29167834
Front Psychiatry. 2022 Feb 15;13:845493
pubmed: 35242066
Mol Psychiatry. 2022 Feb;27(2):784-786
pubmed: 34667263
J Clin Psychiatry. 2000 Jul;61(7):514-7
pubmed: 10937610
J Psychiatr Res. 2006 Apr;40(3):258-66
pubmed: 15907939
Clin Neuropharmacol. 2017 Nov/Dec;40(6):243-245
pubmed: 28976410
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Adv Clin Exp Med. 2021 Aug;30(8):775-778
pubmed: 34418336
Front Psychiatry. 2022 Oct 17;13:1027907
pubmed: 36325532
Br J Psychiatry. 2000 Mar;176:281-4
pubmed: 10755077
J Clin Psychiatry. 2012 Nov;73(11):1395-402
pubmed: 23218156
Singapore Med J. 2011 Jul;52(7):521-5; quiz 526
pubmed: 21808964
Biomedicines. 2021 Jun 25;9(7):
pubmed: 34202246
NPJ Schizophr. 2021 Apr 26;7(1):22
pubmed: 33903594
Diagnostics (Basel). 2020 Aug 26;10(9):
pubmed: 32858974
J Neuropsychiatry Clin Neurosci. 2007 Spring;19(2):145-50
pubmed: 17431060
Am J Psychiatry. 2017 Mar 1;174(3):216-229
pubmed: 27919182
Schizophr Res. 2014 Feb;152(2-3):458-68
pubmed: 24361303
Am J Psychiatry. 2005 Mar;162(3):441-9
pubmed: 15741458
Psychol Assess. 2010 Mar;22(1):180-98
pubmed: 20230164
Neuroimage Clin. 2018 May 23;19:661-674
pubmed: 30023172
Riv Psichiatr. 2012 Mar-Apr;47(2):106-15
pubmed: 22622247
Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56
pubmed: 15000267
Neurosci Bull. 2013 Feb;29(1):59-74
pubmed: 23319314
N Engl J Med. 1992 Aug 27;327(9):604-12
pubmed: 1640954
Compr Psychiatry. 1995 Jan-Feb;36(1):6-10
pubmed: 7705089
Biomedicines. 2021 Feb 26;9(3):
pubmed: 33652776
Schizophr Res. 2016 Mar;171(1-3):35-41
pubmed: 26803693
J Transl Neurosci (Beijing). 2016 Sep;1(1):37-42
pubmed: 29152382
JAMA Psychiatry. 2014 Nov;71(11):1215-21
pubmed: 25188738
Clin Schizophr Relat Psychoses. 2017 Fall;11(3):151-155
pubmed: 25711508
J Psychopharmacol. 2011 May;25(5):567-620
pubmed: 21292923
J Integr Neurosci. 2022 Jul 18;21(5):126
pubmed: 36137959
J Med Life. 2015;8 Spec Issue:74-81
pubmed: 26361516
Am J Psychiatry. 2012 Nov;169(11):1203-10
pubmed: 23034655
Psychosomatics. 2008 Nov-Dec;49(6):540-2
pubmed: 19122133
Front Psychiatry. 2018 Feb 08;9:21
pubmed: 29472876
Pharmacopsychiatry. 2004 Mar;37(2):52-6
pubmed: 15048611
Am J Psychiatry. 1986 Apr;143(4):437-41
pubmed: 3953886
J Psychiatry Neurosci. 2006 May;31(3):157-67
pubmed: 16699601
Schizophr Bull. 2011 Jul;37(4):811-21
pubmed: 19959704
Schizophr Bull. 2013 Jan;39(1):151-60
pubmed: 21799212
Schizophr Bull. 2015 Sep;41(5):1076-83
pubmed: 25512596
Biomedicines. 2022 Dec 08;10(12):
pubmed: 36551945
Brain Cogn. 1995 Mar;27(2):202-12
pubmed: 7772333
Int J Mol Sci. 2022 Jun 23;23(13):
pubmed: 35805990
Am J Psychiatry. 1999 Mar;156(3):400-5
pubmed: 10080555
Biomedicines. 2022 Nov 22;10(12):
pubmed: 36551755
J Psychiatry Neurosci. 2005 May;30(3):187-93
pubmed: 15944743